CORDIS · ALTERNATIVE
environmentAL Toxicity chEmical mixtuRes through aN innovative platform based on aged cardiac tissue model
- Code
ALTERNATIVE- Programme
- H2020
- Call
LC-GD-8-2-2020- Status
- CLOSED
- Period
- 2021-10-01 – 2025-03-31
Official data · CORDIS · synced 2026-10-17 10:16 · official record
Participants
| Organisations | Role | Country | Grant |
|---|---|---|---|
| POLITECNICO DI TORINO | coordinator | IT | 592 300 € |
| FUNDACIO EURECAT | participant | ES | 1 439 438 € |
| CONSIGLIO NAZIONALE DELLE RICERCHE | participant | IT | 569 500 € |
| EURESCOM-EUROPEAN INSTITUTE FOR RESEARCH AND STRATEGIC STUDIES IN TELECOMMUNICATIONS GMBH | participant | DE | 468 250 € |
| SCIENSANO | participant | BE | 460 051 € |
| ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI | participant | IT | 386 750 € |
| ELVESYS | participant | FR | 381 572 € |
| UNIVERSITEIT UTRECHT | participant | NL | 362 500 € |
| IVTECH SRL | participant | IT | 306 750 € |
| MEDIZINISCHE UNIVERSITAT INNSBRUCK | participant | AT | 242 250 € |
| SI ES TI EOOD | participant | BG | 198 750 € |
| MICROFLUIDICS INNOVATION CENTER | participant | FR | 91 647 € |
Description
ALTERNATIVE will develop an innovative platform able to detect the cardiotoxicity of chemicals and their bio-transformation products. The novel platform will enable regulators and industry to identify, quantify and prevent cardiotoxic co-exposures to industrial chemicals and pharmaceuticals in a cost-effective way. ALTERNATIVE will particularly focus on cardiotoxic effects on older people, which is of high relevance in view of the ageing EU population and the high spread of cardiovascular diseases.The platform will consist of a three-dimensional tissue engineering in-vitro model mimicking the human cardiac tissue, coupled with a reliable, high-throughput monitoring system based on multi-omics analyses, and integrated into a Machine Learning (ML) risk assessment tool. In addition, ALTERNATIVE will modify the tissue model to reproduce the aged myocardial tissue and elucidate the adverse effects of chemicals on older people. ALTERNATIVE?s proof-of-concept validation will be performed on well-known mixtures of pollutants, affecting different environmental compartments, and selected via epidemiological, toxicological and modelling expertise.ALTERNATIVE will also provide systematic reviews of high-quality epidemiological studies to support integrated in vitro and in silico data, giving a more robust basis for regulatory decisions.The ALTERNATIVE platform will be an innovative tool for complying with the current regulation associated with the assessment of chemical compounds. It will be a new instrument to evaluate unpredictable toxicity due to synergistic effects of different chemicals, additionally worsened by the human ageing process.By introducing an in vitro cardiac system and ML models, ALTERNATIVE will provide a platform able to refine, reduce and replace the need for animal testing, providing close-to-real scenario information on toxicity and achieving a significant reduction of the associated direct and indirect costs.
Official data · CORDIS · synced 2026-10-17 10:16 · official record · Licence: © European Union, CC BY 4.0 (Commission reuse policy).